Prognostic role of galectin-3 expression in patients with solid tumors: a meta-analysis of 36 eligible studies.

Taken together, our results suggested that galectin-3 played an oncogenic role in colorectal cancer, ovarian cancer and non-small cell lung cancer, indicating it could be a promising biomarker and a novel therapeutic target for them. Further studies were warranted to validate our findings.